Final outcomes from a phase 2 trial of posoleucel in allogeneic hematopoietic cell transplant recipients.
Sanjeet S Dadwal, Rajat Bansal, Michael W Schuster...
https://pubmed.ncbi.nlm.nih.gov/38593233/Actively Recruiting
Led by LucasBio · Updated on 2026-06-26
27
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating the safety and effectiveness of Multi-Virus Specific T cells LB-DTK-MV in treating patients who have antiviral-resistant infections caused by CMV, BKV, or EBV after receiving anticancer treatments or allogeneic hematopoietic stem cell transplantation allo-HSCT. The study aims to determine the maximum tolerated dose, observe changes in viral loads after treatment, and monitor any adverse events following therapy. Participants will receive two intravenous infusions of LB-DTK-MV. The first infusion is given at the baseline visit at either a low dose 1x107m2 or high dose 2x107m2. A second infusion at the same dose is administered 14 days later. The LB-DTK-MV is a biological cell therapy product derived from a donor and prepared as a cell suspension that is thawed before use. During the study, participants will have weekly follow-up visits at the clinic for six months after the first infusion. Researchers will assess viral loads for CMV, BKV, and EBV, monitor immune responses, and record any treatment-related adverse events throughout the 24 weeks after treatment starts. Various tests including vital signs, physical exams, lab tests, and electrocardiograms will be performed to ensure participant safety and track outcomes.
CONDITIONS
Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infection or Associated Diseases Following Anticancer Therapy or Allogeneic Hematopoietic Stem Cell Transplantation.
N
Nayoun Kim, Ph.D.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
LucasBio
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening visit
Duration - 2 weeks
Participants receive two intravenous infusions of LB-DTK-MV cell therapy, with the second infusion given 14 days after the first.
2 visits for infusions
Duration - 24 weeks
Participants attend weekly clinic visits for 6 months to monitor viral loads, immune response, and any treatment-related side effects.
Weekly visits
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Sanjeet S Dadwal, Rajat Bansal, Michael W Schuster...
https://pubmed.ncbi.nlm.nih.gov/38593233/Claudio Annaloro, Fabio Serpenti, Giorgia Saporiti...
https://pubmed.ncbi.nlm.nih.gov/33552044/Seok-Goo Cho, Nayoun Kim, Hyun-Jung Sohn...
https://pubmed.ncbi.nlm.nih.gov/26017177/Arsalan Jalili, Abbas Hajifathali, Mozhdeh Mohammadian...
https://pubmed.ncbi.nlm.nih.gov/37646062/Spyridoula Vasileiou, LaQuisa Hill, Manik Kuvalekar...
https://pubmed.ncbi.nlm.nih.gov/36373249/Theresa Kaeuferle, Ramona Krauss, Franziska Blaeschke...
https://pubmed.ncbi.nlm.nih.gov/30728058/Ifigeneia Tzannou, Anastasia Papadopoulou, Swati Naik...
https://pubmed.ncbi.nlm.nih.gov/28783452/Juan C Gea-Banacloche
https://pubmed.ncbi.nlm.nih.gov/23813935/Conrad Russell Cruz, Patrick J Hanley, Hao Liu...
https://pubmed.ncbi.nlm.nih.gov/20429793/Spyridoula Vasileiou, Manik Kuvalekar, Yovana Velazquez...
https://pubmed.ncbi.nlm.nih.gov/38597860/LucasBio
Lead Sponsor